Latest Us Market News

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

Talga Group has successfully raised A$7.3 million through an oversubscribed Share Purchase Plan, surpassing its A$5 million target to fund a significant ramp-up in graphite anode production and support strategic growth initiatives.

AnteoTech has raised A$3.5 million through a discounted share placement to accelerate commercialisation of its advanced battery and life sciences technologies globally. The capital injection supports strategic partnerships and sales expansion in key markets including the US and India.

HeraMED Limited has completed a $3.2 million placement to fund its global rollout of digital maternity care solutions, backed by new and existing institutional investors.

Energy Transition Minerals Ltd (ETM) reported key progress in its December 2025 quarter, including legal developments for its Greenland rare earth project, advancing a strategic mine acquisition in Spain, and moves toward a US Nasdaq listing.

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.

Pureprofile Limited has upgraded its FY26 revenue guidance after a record first half, driven by strong international growth and a booming platform business. The Rest of World segment now outpaces ANZ, signalling a major shift in the company’s geographic footprint.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.